Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Add as a preferred source on Google
NEW YORK, Feb. 27, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Inotek Pharmaceuticals Corporation (“Inotek”) (NASDAQ:ITEK) between July 23, 2015 and December 30, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
http://www.zlk.com/pslra/inotek-pharmaceuticals-corporation
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Inotek misrepresented the efficacy of its drug candidate trabodenoson—the only drug Inotek currently has in its clinical development pipeline—and its attendant capacity to receive New Drug Approval by the U.S. Food and Drug Administration. In particular, it is alleged that the Company made positive statements about the drug despite knowledge that the MATrX-1 phase 3 clinical trial of trabodenoson would fail to meet its primary endpoint of statistical relevance in the reduction of intraocular pressure compared with placebo.
On January 3, 2017, Inotek announced that the Phase 3 trial of trabodenoson had failed to achieve this primary endpoint. Following this news, shares of Inotek fell from a closing price of $6.10 on December 30, 2016, to a closing price of of $1.75 per share on January 3, 2017.
If you suffered a loss in Inotek you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
